Novel CD2-targeted bispecific antibody enhances T cell engagers for solid tumors
A novel CD2-targeted bispecific antibody combined with CD3 T cell engager shows improved efficacy and reduced toxicity in solid tumors.
Therapeutic Area
Therapeutic area intelligence for Bispecific Antibodies with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.